Table 1 Univariate and multivariate Cox regression analysis of factors associated with overall survival of patients with HCC.

Age (≥71 years)

0.816

0.415–1.603

0.555

Sex (male)

1.005

0.498–2.030

0.988

HBV (positive)

1.376

0.525–3.611

0.516

HCV (positive)

0.517

0.263–1.014

0.055

Child-Pugh (≥6)

1.632

0.802–3.322

0.177

Platelets (≥111 × 10³/mm3)

1.511

0.769–2.969

0.231

Hemoglobin (≥12.6 g/dL)

0.490

0.000–0.971

0.041

0.630

0.315–1.260

0.192

Albumin (≥3.5 g/dL)

0.462

0.000–0.920

0.028

0.554

0.264–1.165

0.119

AST (≥55 U/L)

1.198

0.605–2.372

0.603

ALT (≥40 U/L)

0.861

0.436–1.699

0.666

AFP (≥200 ng/mL)

1.416

0.715–2.805

0.318

AFP-L3% (≥5%)

1.766

0.890–3.505

0.104

DCP (≥200 mAU/mL)

2.235

1.103–4.532

0.026

1.773

0.827–3.799

0.141

Sorafenib dose (800 mg/day)

0.945

0.474–1.884

0.873

Vascular invasion or distant metastasis (positive)

1.533

0.776–3.029

0.219

sBTLA (≥395 pg/mL)

2.105

1.062–4.170

0.033

2.095

1.040–4.220

0.038

sCD27 (≥4500 pg/mL)

0.751

0.383–1.471

0.404

sCD28 (≥4000 pg/mL)

0.904

0.453–1.804

0.775

sTIM-3 (≥5500 pg/mL)

0.862

0.442–1.682

0.663

sHVEM (≥2500 pg/mL)

1.066

0.546–2.080

0.852

sCD40 (≥650 pg/mL)

1.447

0.744–2.817

0.277

sGITR (≥50 pg/mL)

1.246

0.640–2.427

0.517

sLAG-3 (≥21500 pg/mL)

0.816

0.418–1.594

0.552

sTLR-2 (≥900 pg/mL)

0.808

0.411–1.587

0.536

sGITRL (≥180 pg/mL)

0.789

0.402–1.549

0.492

sPD-1 (≥610 pg/mL)

1.521

0.764–3.029

0.232

sCTLA-4 (≥30.5 pg/mL)

0.777

0.394–1.535

0.468

sCD80 (≥82 pg/mL)

0.913

0.462–1.806

0.794

sCD86 (≥825 pg/mL)

0.633

0.322–1.242

0.183

sPD-L1 (≥42 pg/mL)

0.807

0.411–1.581

0.531

sICOS (≥240 pg/mL)

0.894

0.457–1.749

0.744